menu

Expert Answers to Common Questions for Who’s at Risk? Preventing and Managing Tumor Lysis Syndrome and Neutropenia in CLL

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Expert Answers to Common Questions for Who’s at Risk? Preventing and Managing Tumor Lysis Syndrome and Neutropenia in CLL

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Many CLL treatments cause a high risk for tumor lysis syndrome (TLS), an oncologic emergency due to the release of intracellular contents of tumor cells characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte imbalances may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, loss of muscle control, and even death. In addition, neutropenia is a common side effect associated with CLL therapies, which increases the risk for infection and can disrupt or delay treatment, ultimately affecting patient outcomes.

    A greater understanding of assessment and management of TLS and neutropenia is critical for reducing the likelihood of life-threatening complications in patients with CLL, which allows patients to continue to receive treatment.

    AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on preventing and managing tumor lysis syndrome and neutropenia in CLL.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: Matthew S. Davids, MMSc, MD, reported a financial interest/relationship or affiliation in the form of Advisor: AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca Pharmaceuticals LP; BeiGene LTD; Celgene Corp; Genentech, Inc; Janssen Oncology; MEI Pharma; Pharmacyclics, Inc; TG Therapeutics, Inc; and Verastem Inc. Contracted research: Ascentage Pharma; AstraZeneca Pharmaceuticals LP; Genentech, Inc; MEI Pharma; Pharmacyclics, Inc; Surface Pharmaceuticals, Inc; and Verastem Inc. Honoraria: Research to Practice.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Adrienne N. Nedved, MPA, PharmD, BCOP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This activity is intended for hematologists, advanced practitioners (physician assistants, nurses, pharmacists), and other healthcare professionals involved in the care of patients with CLL at risk for TLS and neutropenia.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify patients with chronic lymphocytic leukemia at risk of developing tumor lysis syndrome
    • Implement appropriate prophylactic measures for patients with chronic lymphocytic leukemia based on risk for the prevention of tumor lysis syndrome
    • Develop strategies for the early identification, monitoring, and management of patients with chronic lymphocytic leukemia who develop tumor lysis syndrome based on current guidelines
    • Employ approaches to assess and manage neutropenia in patients with chronic lymphocytic leukemia
    • Apply effective patient risk-stratification measures for TLS and neutropenia
  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits.  Approval is valid until 01/06/2023. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education JA4008106-0000-21-101-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Disclaimer

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    Supported by an educational grant from Genentech, a member of the Roche Group.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Many CLL treatments cause a high risk for tumor lysis syndrome (TLS), an oncologic emergency due to the release of intracellular contents of tumor cells characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. These electrolyte imbalances may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, loss of muscle control, and even death. In addition, neutropenia is a common side effect associated with CLL therapies, which increases the risk for infection and can disrupt or delay treatment, ultimately affecting patient outcomes.

    A greater understanding of assessment and management of TLS and neutropenia is critical for reducing the likelihood of life-threatening complications in patients with CLL, which allows patients to continue to receive treatment.

    AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on preventing and managing tumor lysis syndrome and neutropenia in CLL.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: Matthew S. Davids, MMSc, MD, reported a financial interest/relationship or affiliation in the form of Advisor: AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca Pharmaceuticals LP; BeiGene LTD; Celgene Corp; Genentech, Inc; Janssen Oncology; MEI Pharma; Pharmacyclics, Inc; TG Therapeutics, Inc; and Verastem Inc. Contracted research: Ascentage Pharma; AstraZeneca Pharmaceuticals LP; Genentech, Inc; MEI Pharma; Pharmacyclics, Inc; Surface Pharmaceuticals, Inc; and Verastem Inc. Honoraria: Research to Practice.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Adrienne N. Nedved, MPA, PharmD, BCOP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This activity is intended for hematologists, advanced practitioners (physician assistants, nurses, pharmacists), and other healthcare professionals involved in the care of patients with CLL at risk for TLS and neutropenia.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify patients with chronic lymphocytic leukemia at risk of developing tumor lysis syndrome
    • Implement appropriate prophylactic measures for patients with chronic lymphocytic leukemia based on risk for the prevention of tumor lysis syndrome
    • Develop strategies for the early identification, monitoring, and management of patients with chronic lymphocytic leukemia who develop tumor lysis syndrome based on current guidelines
    • Employ approaches to assess and manage neutropenia in patients with chronic lymphocytic leukemia
    • Apply effective patient risk-stratification measures for TLS and neutropenia
  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits.  Approval is valid until 01/06/2023. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education JA4008106-0000-21-101-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Disclaimer

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    Supported by an educational grant from Genentech, a member of the Roche Group.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule26 Jan 2022
Webpack App